Pharmacotherapy of ovarian hyperstimulation syndrome

Bibliography

• Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006;27(2):170-207
   Google Scholar
• Abramov Y, Elchalal U, Schenker JG. Severe OHSS: an ‘epidemic’ of severe OHSS: a price we have to pay? Hum Reprod 1999;14(9):2181-3
   Google Scholar
• Enskog A, Henriksson M, Unander M, Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999;71(5):808-14
   Google Scholar
• Whelan JG III, Vlahos ENF. The ovarian hyperstimulation syndrome. Fertil Steril 2000;11(5):883-96
   Google Scholar
• Golan A, Ron-El R, Hoffman A, CASPI. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430-40. 4
   PubMedGoogle Scholar
• Gianaroli L, Ferraretti AP, Magli EMC. Pathophysiology of ovarian hyperstimulation syndrome (OHSS). Volume 1. Serono fertility series; 1997. p. 11-20
   Google Scholar
• Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58(2):249-61
   Google Scholar
• Daelemans C, Smits G, De Maertelaer V, Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab 2004;89(12):6310-5
   Google Scholar
• Pellicer A, Albert C, Mercader A, The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999;71(3):482-9
   Google Scholar
• Niederberger V, Rottensteiner-Grohsmann C, Turnheim K, Incidence of ovarian hyperstimulation syndrome in in-vitro-fertilization treatment over a period of 11 years. Wien Med Wochenschr. 1995;145(23):642-5
   Google Scholar
• Qasim SM, Karacan M, Kemmann E. An eight year review of hospitalization for ovarian hyperstimulation syndrome. Clin Exp Obstet Gynecol 1997;24(2):49-52
   Google Scholar
• Agrawal R, Holmes J, Jacobs HS. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis. Fertil Steril 2000;73(2):338-43
   Google Scholar
• Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 1997;67(2):261-5
   Google Scholar
• Goldsman MP, Pedram A, Dominguez CE, Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 1995;63(2):268-72
   Google Scholar
• Neulen J, Yan Z, Raczek S, Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995;80(6):1967-71
   Google Scholar
• Albert C, Garrido N, Mercader A, The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod 2002;8(5):409-18
   Google Scholar
• Rizk B, Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod 1991;6(8):1082-7
   Google Scholar
• Zosmer A, Katz Z, Lancet M, Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril 1987;47(3):524-6
   Google Scholar
• Ferraretti AP, Gianaroli L, Fiorentino EA. The ovarian hyperstimulation syndrome (OHSS): definition, clinical symptons, classification and incidence. Volume 1. Serono fertility series; 1997. p. 1-102
   Google Scholar
• Royal college of obstetricians and gynaecologists. The management of ovarian hyperstimulation syndrome. Green-top Guideline No. 5 September 2006
   Google Scholar
• Balasch J, Carmona F, Llach J, Acute prerenal failure and liver dysfunction in a patient with severe ovarian hyperstimulation syndrome. Hum Reprod 1990;5:348-51
   PubMed Web of Science ®Google Scholar
• Evbuomwan IO, Davison JM, Murdoch AP. Coexistent hemoconcentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostasis paradox. Fertil Steril 2000;74:67-72
   PubMedGoogle Scholar
• Abramov Y, Elchalal U, Schenker JG. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1999;71:645-51
   PubMed Web of Science ®Google Scholar
• Bates SM, Greer IA, Pabinger I, ; American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Edition. Chest 2008;133(6 Suppl):844S-886S
   Google Scholar
• Golan A, Ron-El R, Herman A, Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization. Fertil Steril 1988;50(6):912-16
   Google Scholar
• Brinsden PR, Wada I, Tan SL, Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995;102(10):767-72
   PubMedGoogle Scholar
• Aboulghar MA, Mansour RT, Serour GI, Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome. Fertil Steril 1996;66(5):757-60
   Google Scholar
• Homburg R, Howles CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update 1999;5(5):493-9
   Google Scholar
• El-Sheikh MM, Hussein M, Fouad S, Limited ovarian stimulation (LOS), prevents the recurrence of severe forms of ovarian hyperstimulation syndrome in polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 2001;94(2):245-9
   Google Scholar
• Bider D, Menashe Y, Oelsner G, Ovarian hyperstimulation syndrome due to exogenous gonadotropin administration. Acta Obstet Gynecol Scand 1989;68(6):511-14
   Google Scholar
• Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Hum Reprod 1992;7(3):320-7
   Google Scholar
• Dale PO, Tanbo T, Abyholm T. In-vitro fertilization in infertile women with the polycystic ovarian syndrome. Hum Reprod 1991;6(2):238-41
   Google Scholar
• MacDougall MJ, Tan SL, Balen A, Jacobs HS. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod 1993;8(2):233-7
   Google Scholar
• Lass A, Vassiliev A, Decosterd G, Relationship of baseline ovarian volume to ovarian response in World Health Organization II anovulatory patients who underwent ovulation induction with gonadotropins. Fertil Steril 2002;78(2):265-9
   Google Scholar
• Delvigne A, Vandromme J, Demeestere I, Leroy F. Unpredictable cases of complicated ovarian hyperstimulation in IVF. Int J Fertil Womens Med 1997;42(4):268-70
   Google Scholar
• Papanikolaou EG, Pozzobon C, Kolibianakis EM, Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85(1):112-20
   Google Scholar
• Mansour R, Aboulghar M, Serour G, Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 2005;20(11):3167-72
   Google Scholar
• Tortoriello DV, McGovern PG, Colon JM, ‘Coasting’ does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertil Steril 1998;69(3):454-60
   Google Scholar
• Sher G, Zouves C, Feinman M, Maassarani G. ‘Prolonged coasting’: an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Hum Reprod 1995;10(12):3107-9
   Google Scholar
• Gustofson RL, Segars JH, Larsen FW. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod 2006;21(11):2830-7
   Google Scholar
• Aboulghar MA, Mansour RT, Amin YM, A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reprod Biomed Online 2007;15(3):271-9
   Google Scholar
• Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010; In press
   Google Scholar
• Aboulghar MA, Mansour RT, Amin YM, Prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reprod Biomed Online 2007;15(3):271-9
   Google Scholar
• Khattab S, Fotouh IA, Mohesn IA, Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach. Reprod Biomed Online 2006;13(2):194-7
   Google Scholar
• Tang T, Glanville J, Orsi N, The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 2006;21(6):1416-25
   Google Scholar
• Shoham Z, Weissman A, Barash A, Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertil Steril 1994;62(1):137-42
   Google Scholar
• Jee BC, Suh CS, Kim YB, Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. Gynecol Obstet Invest 2010;70(1):47-54
   Google Scholar
• Aboulghar M, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome [review]. Cochrane Database Syst Rev 2002;(2):CD001302
   Google Scholar
• Konig E, Bussen S, Sutterlin M, Steck T. Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. Hum Reprod 1998;13(9):2421-4
   Google Scholar
• Nargund G, Hutchison L, Scaramuzzi R, Campbell S. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod Biomed Online 2007;14(6):682-5
   Google Scholar
• Driscoll GL, Tyler JP, Hangan JT, A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Hum Reprod 2000;15(6):1305-10
   Google Scholar
• Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization. Fertil Steril 2004;82(4):841-6
   Google Scholar
• Diedrich K, Ludwig M, Felberbaum RE. The role of gonadotrophin-releasing hormone antagonists in in vitro fertilization. Semin Reprod Med 2001;19:213-20
   PubMed Web of Science ®Google Scholar
• Babayof R, Margalioth EJ, Huleihel M, Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006;21(5):1260-5
   Google Scholar
• Engmann L, Diluigi A, Schmidt D, The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008;89(1):84-91
   Google Scholar
• Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006;12(2):159-68
   Google Scholar
• Carizza C, Abdelmassih V, Abdelmassih S, Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008;17(6):751-5
   Google Scholar
• Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147(11):5400-11
   Google Scholar
• Alvarez C, Alonso-Muriel I, Garcia G, Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007;22(12):3210-14
   Google Scholar
• Youssef MA, Van Wely M, Hassan MA, Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010; In press
   Google Scholar
• Busso CE, Garcia-Velasco J, Gomez R, Symposium: update on prediction and management of OHSS. Prevention of OHSS–dopamine agonists. Reprod Biomed Online 2009;19(1):43-51
   Google Scholar
• Busso C, Fernandez-Sanchez M, Garcia-Velasco JA, The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod 2010;25(4):995-1004
   Google Scholar